Check out what we have in store for you in the March Newsletter
This month’s HCV Advocate newsletter is full of valuable information about hepatitis C.
Harvoni: The Food and Drug Administration has granted Gilead new indications to treat people with HCV genotype 1 and 4 pre- and post-liver transplant. Read about the new indications along with the very high cure rates for people who have the highest need for treatment.
RG-101 is an injectable drug that has mid-study results. RG-101 is given at Day 1 and Day 29 along with currently approved HCV direct-acting antivirals. Check out the results – very impressive. These drugs have the potential to produce high cure rates and shorter treatment durations. A very intriguing new study is listed at the end of HCV Drugs.
HealthWise –by Lucinda K. Porter, RN
Hepatitis C Treatment and Cirrhosis – Lucinda discusses the importance of treating people with cirrhosis in this timely article to coincide with the FDA approval of the new indications for Harvoni.
SnapShots by Alan Franciscus
In this month’s Snapshots, I discuss treatment of decompensated cirrhosis with direct-acting antivirals, the use of statins in people with compensated cirrhosis, and an analysis of Harvoni (ledipasvir/sofosbuvir) phase 3 studies that compare the cure rates of blacks vs. non-black patients.
What’s Up! We have the following topics to tell you about:
Basics: We have updated this valuable module that includes the latest basic information about hepatitis C.
Have an Event? List it on the HCV Advocate by following this link.
That’s All Folks!
Alan and the staff of the HCV Advocate!